secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYCOR MEDICAL INC (VYCO)
CIK:        0001424768
Form:       8-K
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0001641172-25-022715
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vycor Medical Q2 revenue up 22% to $496K; VBAS division drives growth with new international distribution
--------------------------------------------------------------------------------

- Q2 total revenue $496,353 (+22% YoY); Vycor Medical (VBAS) up 24% to $481,788, led by international markets.
- GAAP operating profit Q2 $51,146; non-GAAP operating profit $84,481, up from $31,859 in Q2 2024.
- Gross margin fell to 83% from 91% due to validation/shipping costs of new production and sales mix.
- Entered new distribution agreements for France and Spain during H1 2025, targeting key international markets.
- Two new peer-reviewed VBAS clinical papers published in Q2; total now 48. NovaVision study validates NeuroEyeCoach for home/clinic.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1424768/000164117225022715/0001641172-25-022715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1424768/000164117225022715/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-022715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer